A Combinatorial Approach to Wound Healing for Protein, Gene and Cell Therapeutics

蛋白质、基因和细胞治疗的伤口愈合组合方法

• 批准号: 7815960
• 负责人: ANDREW BAIRD
• 金额: $ 42.02万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7815960
• 关键词: Agonist; Bacteria; Benchmarking; Biological Assay; Biotechnology; Cancer Center Planning Grant; Cells; Communities; Contracts; Development; Disease; Employment; Enzyme-Linked Immunosorbent Assay; Funding; Gene Proteins; Genes; Grant; Hour; Injury; Laboratories; Lead; Licensing; Luciferases; Maps; Measurable; Measures; Modeling; Molecular Cloning; Monoclonal Antibodies; Mus; Neuropeptides; Occupations; Outcome; Parents; Peptides; Pharmaceutical Preparations; Physiological; Positioning Attribute; Pre-Clinical Model; Preclinical Drug Evaluation; Private Sector; Process; Proteins; Recombinants; Recruitment Activity; Reporter; Research; Research Project Grants; Role; Specificity; Technology; Technology Transfer; Testing; Therapeutic; Time; Transgenic Mice; Wound Healing; Zebrafish; analog; combinatorial; commercialization; drug candidate; drug development; drug discovery; human disease; knock-down; novel diagnostics; novel therapeutics; parent grant; parent project; programs; promoter; receptor; skills; success; technology development; therapeutic development

DESCRIPTION (provided by applicant): We propose an 14 month, milestone-driven, benchmarked research plan that extends a parent P20 Center grant focusing on bio-therapeutics development. The research will initially be executed by 6 newly hired academic research and technical positions at UCSD. Sustained and new employment in drug discovery, drug screening and drug development will be developed by partnerships with the San Diego's local biotechnology community. Specifically we will: (1) express a newly discovered recombinant neuropeptide protein that we identified in the parent grant (P20 GM078421). Analogs will be synthesized to identify functional domains and test agonists and antagonists. (2) develop high specificity monoclonal antibodies and create a quantitative ELISA assay to measure its role in disease. (3) evaluate preclinical models of wound repair by creating models of gene knock down and conditional knock outs to (a) establish its physiological relevance, (b) serve as models for drug discovery and (c) assist in converting the drug candidate to a drug lead. (4) identify its receptor by molecular cloning to establish an assay for drug discovery. (5) map the promoter to create a luciferase reporter transgenic mouse. (6) transfer technology generated to the private sector for further development. Funding will build on the success of the parent project, extend its scope, bring new fundamental skills to the laboratory, accelerate the tempo of scientific research and allow for significant job creation (and retention) by enabling hiring of additional staff, increasing hours of current part-time staff, and contracting for additional needed skills. The funded program will create 6 new full time positions, enable us to sustain 2 ongoing current research positions and with a successful outcome, we anticipate would generate an additional 5-15 new jobs in drug development research positions by technology transfer to the private biotechnology sector. Relevance: This research project describes 5 milestone and bench-marked specific AIMs that will create, test and validate a new therapeutic for wound healing. It will immediately create 6 full time positions and, if successful, its 6th AIM will create 5-15 new jobs by technology transfer to the private sector.

描述（由申请人提供）：我们提出一项为期14个月、里程碑驱动的基准研究计划，该计划扩展了专注于生物治疗开发的父P20中心拨款。这项研究最初将由加州大学圣地亚哥分校新聘用的6个学术研究和技术职位执行。通过与圣地亚哥当地生物技术社区的合作，将在药物发现、药物筛选和药物开发方面提供持续和新的就业机会。具体来说，我们将：(1)表达我们在亲本基金（P20 GM078421）中鉴定的新发现的重组神经肽蛋白。将合成类似物来鉴定功能域和测试激动剂和拮抗剂。(2)研制高特异性单克隆抗体，建立定量ELISA检测方法，测定其在疾病中的作用。(3)通过创建基因敲低和条件敲除模型来评估伤口修复的临床前模型，以(a)建立其生理学相关性，(b)作为药物发现模型，(c)协助将候选药物转化为药物先导。(4)通过分子克隆鉴定其受体，建立药物发现的检测方法。(5)对启动子进行定位，构建荧光素酶报告基因转基因小鼠。(6)将产生的技术转让给私营部门以供进一步发展。资金将建立在母项目成功的基础上，扩大其范围，为实验室带来新的基本技能，加快科学研究的节奏，并通过雇用额外的工作人员，增加现有兼职工作人员的工作时间，以及签订额外所需技能的合同，从而创造（和保留）大量的就业机会。受资助的项目将创造6个新的全职职位，使我们能够维持2个正在进行的研究职位，如果结果成功，我们预计将通过向私营生物技术部门转移技术，在药物开发研究职位上创造额外的5-15个新工作岗位。

项目成果

Targeting the gut barrier: identification of a homing peptide sequence for delivery into the injured intestinal epithelial cell.

• DOI: 10.1016/j.surg.2009.05.007
• 发表时间: 2009-08
• 期刊: SURGERY
• 影响因子: 3.8
• 作者: Costantini, Todd W.;Putnam, James G.;Sawada, Ritsuko;Baird, Andrew;Loomis, William H.;Eliceiri, Brian P.;Bansal, Vishal;Coimbra, Raul
• 通讯作者: Coimbra, Raul

Pentoxifylline modulates intestinal tight junction signaling after burn injury: effects on myosin light chain kinase.

• DOI: 10.1097/ta.0b013e318191bb1f
• 发表时间: 2009-01
• 期刊: The Journal of trauma
• 作者: Costantini TW;Loomis WH;Putnam JG;Kroll L;Eliceiri BP;Baird A;Bansal V;Coimbra R
• 通讯作者: Coimbra R

Ecrg4 expression and its product augurin in the choroid plexus: impact on fetal brain development, cerebrospinal fluid homeostasis and neuroprogenitor cell response to CNS injury.

• DOI: 10.1186/2045-8118-8-6
• 发表时间: 2011-01-18
• 期刊: Fluids and barriers of the CNS
• 影响因子: 7.3
• 作者: Gonzalez AM;Podvin S;Lin SY;Miller MC;Botfield H;Leadbeater WE;Roberton A;Dang X;Knowling SE;Cardenas-Galindo E;Donahue JE;Stopa EG;Johanson CE;Coimbra R;Eliceiri BP;Baird A
• 通讯作者: Baird A

Pulmonary preconditioning, injury, and inflammation modulate expression of the candidate tumor suppressor gene ECRG4 in lung.

• DOI: 10.3109/01902148.2014.983282
• 发表时间: 2015-04
• 期刊: Experimental lung research
• 影响因子: 1.7
• 作者: Kao S;Shaterian A;Cauvi DM;Dang X;Chun HB;De Maio A;Costantini TW;Coimbra R;Eliceiri BP;Baird A
• 通讯作者: Baird A

Co-localization and regulation of basic fibroblast growth factor and arginine vasopressin in neuroendocrine cells of the rat and human brain.

• DOI: 10.1186/1743-8454-7-13
• 发表时间: 2010-08-13
• 期刊: Cerebrospinal fluid research
• 作者: Gonzalez AM;Taylor WM;Johanson CE;King JC;Leadbeater WE;Stopa EG;Baird A
• 通讯作者: Baird A